Brief: Syndax Plans To Advance Into Phase 1B Portion Of Trial Evaluating Revumenib In Relapsed Or Refractory Metastatic MSS CRC
06/06/2024 13:16
June 6 (Reuters) - Syndax Pharmaceuticals Inc SNDX.O :
* SYNDAX ANNOUNCES PLANS TO ADVANCE INTO PHASE 1B PORTION OF
TRIAL
EVALUATING REVUMENIB IN RELAPSED OR REFRACTORY METASTATIC MSS
CRC
Source text for Eikon: ID:nPnb7YYjla
Further company coverage: SNDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million